Checkpoint inhibitors: What gastroenterologists need to know

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology
• Hepatology
• Pancreatology

Background:

• Checkpoint inhibitors represent a significant advancement in cancer therapy.
• Their clinical use is expanding, necessitating awareness of potential toxicities.
• Gastrointestinal, hepatic, and pancreatic side effects are among the serious adverse events associated with these agents.

Purpose of the Study:

• To provide a comprehensive overview of checkpoint inhibitors.
• To detail the mechanisms of action and indications for various checkpoint inhibitors.
• To outline the evaluation and management strategies for gastrointestinal, hepatic, and pancreatic side effects.

Main Methods:

• Review of current literature on checkpoint inhibitors and their associated toxicities.
• Discussion of clinical practice guidelines for managing immune-related adverse events.
• Synthesis of information regarding the specific side effect profiles of different checkpoint inhibitors.

Main Results:

• Checkpoint inhibitors, while effective, are associated with a spectrum of gastrointestinal, hepatic, and pancreatic toxicities.
• Early recognition and appropriate management are crucial for mitigating the severity of these side effects.
• Understanding the mechanism of action aids in predicting and managing specific adverse events.

Conclusions:

• Effective management of gastrointestinal, hepatic, and pancreatic side effects is essential for safe and continued use of checkpoint inhibitors.
• Clinicians require up-to-date knowledge on the indications, mechanisms, and toxicity profiles of these immunotherapies.
• Proactive monitoring and timely intervention can significantly improve patient outcomes in the context of checkpoint inhibitor therapy.